Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on the U.S. Food and Drug Administration’s review timeline for a potential focal ...

Travere Therapeutics (TVTX) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.73 per share a year ago. These figures are ...

FILSPARI generated $103.3 million in U.S. net product sales for Q4 and $322 million for the full year. Thiola and Thiola EC contributed $23.3 million in U.S. net product sales during Q4 and $88.5 ...

The drug developer posted revenue of $129.7 million in the period, which did not meet Street forecasts. Six analysts surveyed ...

Travere Therapeutics (NASDAQ: TVTX) reported its Q4 earnings results on Thursday, February 19, 2026 at 04:01 PM. Here's what investors need to know about the announcement. Travere Therapeutics beat ...

For the quarter ended December 2025, Travere Therapeutics (TVTX) reported revenue of $129.69 million, up 73.4% over the same period last year. EPS came in at $0.03, compared to -$0.73 in the year-ago ...

Genomics, Inc. , a leader in single cell and spatial biology, announced today that members of its management team will ...

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of ...

Healthcare Investors reported an 8.43% NAV return for Q4 2025. Read the full analysis for insights on sector strategy and ...